- Home
- IPHA vs CBUS Comparison
IPHA vs CBUS Comparison
Compare IPHA & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- CBUS
- Stock Information
- Founded
- IPHA 1999
- CBUS 2010
- Country
- IPHA France
- CBUS United States
- Employees
- IPHA N/A
- CBUS N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- CBUS Agricultural Chemicals
- Sector
- IPHA Health Care
- CBUS Industrials
- Exchange
- IPHA Nasdaq
- CBUS Nasdaq
- Market Cap
- IPHA 191.0M
- CBUS 160.8M
- IPO Year
- IPHA 2019
- CBUS 2017
- Fundamental
- Price
- IPHA $2.28
- CBUS $5.00
- Analyst Decision
- IPHA Strong Buy
- CBUS Strong Buy
- Analyst Count
- IPHA 1
- CBUS 3
- Target Price
- IPHA $11.50
- CBUS $23.67
- AVG Volume (30 Days)
- IPHA 6.3K
- CBUS 141.3K
- Earning Date
- IPHA 09-12-2024
- CBUS 11-07-2024
- Dividend Yield
- IPHA N/A
- CBUS N/A
- EPS Growth
- IPHA N/A
- CBUS N/A
- EPS
- IPHA N/A
- CBUS N/A
- Revenue
- IPHA $36,202,722.00
- CBUS $2,961,000.00
- Revenue This Year
- IPHA N/A
- CBUS $36.93
- Revenue Next Year
- IPHA $105.84
- CBUS $236.45
- P/E Ratio
- IPHA N/A
- CBUS N/A
- Revenue Growth
- IPHA N/A
- CBUS 816.72
- 52 Week Low
- IPHA $1.81
- CBUS $4.26
- 52 Week High
- IPHA $3.15
- CBUS $23.18
- Technical
- Relative Strength Index (RSI)
- IPHA 50.55
- CBUS 35.69
- Support Level
- IPHA $2.27
- CBUS $4.77
- Resistance Level
- IPHA $2.41
- CBUS $5.50
- Average True Range (ATR)
- IPHA 0.11
- CBUS 0.65
- MACD
- IPHA -0.00
- CBUS -0.05
- Stochastic Oscillator
- IPHA 52.94
- CBUS 26.61
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.